Particle Therapy Co-Operative Group

An organisation for those interested in proton, light ion and heavy charged particle radiotherapy

BNCT Subcommittee

The BNCT Subcommittee was established at the PTCOG 60 Conference in Miami.

 

Co-Chairs:

This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it.

Relevant topics include, but are not limited to, the following:

  • Radiation biology for BNCT;
  • Cell-based studies;
  • Preclinical animal studies;
  • Drug development for BNCT;
  • Impact of BNCT on the proteomic profile and omics approaches;
  • Boron imaging;
  • Mechanisms of action of BNCT;
  • Abscopal effect of BNCT;
  • Early clinical trials;
  • Biomarkers for therapeutic optimization.

 

Bibliogarphy (collected by This email address is being protected from spambots. You need JavaScript enabled to view it.): 

1. Virtual IAEA Technical Meeting on Advances in Boron Neutron Capture Therapy. July 2020.

2. The basis and advances in clinical application of boron neutron capture therapy,
     
Radiation Oncology volume 16, Article number: 216 (2021)

3. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system.

4. Boron Neutron Capture Therapy: A Review of Clinical Applications.

5. Clinical viability of Boron Neutron Capture Therapy for personalized radiation treatment 

6. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial  

7. Prospects for the new era of boron neutron capture therapy and subjects for the future. Ono 2018

8.A Review of Boron Neutron Capture Therapy: Its History and Current Challenges.
    Int J Part Ther (2022) 9 (1): 71–82.